Available Technologies

# of Displayed Technologies: 2 / 2

Categories

Therapuetic Agent for B Cell Malignancies
TS-015099 — A small molecule that functions as an agonist of the sphingosine receptor mediated signaling and interferes with lymphocyte trafficking.
In 2020, there will be an estimated 200,000 new cases of blood cancer in the United States. Blood cancer such as chronic lymphocytic leukemia (CLL), Non-Hodgkin's Lymphoma (NHL), and acute lymphoblastic leukemia (ALL) are typically treated with a combination of chemotherapy, radiation, and bio…
  • College: College of Medicine (COM)
  • Inventors: Byrd, John; Chen, Ching-Shih; Muthusamy, Natarajan; Perrotti, Danilo
  • Licensing Officer: Ezzell, Janel
Novel Protein Kinase C Delta Activators
TS-014754 — A novel anti-cancer agent (OSU-2S) that is devoid of S1P1 receptor activity and is highly effective in suppressing hepatocellular carcinoma tumor growth in vivo.
The third leading cause of cancer death worldwide is hepatocellular carcinoma (HCC). Due to the rise in the incidence of hepatitis C virus infection, HCC is expected to increase in the United States. Many patients with HCC are not candidates for surgery because of the location or size of their tum…
  • College: College of Pharmacy
  • Inventors: Chen, Ching-Shih; Byrd, John; Kulp, Samuel; Muthusamy, Natarajan; Wang, Dasheng
  • Licensing Officer: Davis, Stewart

Loading icon